Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2016

01-09-2016 | Original Article

Prognostic impact of RUNX1 and ETV6 gene copy number on pediatric B-cell precursor acute lymphoblastic leukemia with or without hyperdiploidy

Authors: Nuket Yurur Kutlay, Esra Pekpak, Sule Altıner, Talia Ileri, Arzu Nedime Vicdan, Handan Dinçaslan, Elif Unal Ince, Fatma Ajlan Tukun

Published in: International Journal of Hematology | Issue 3/2016

Login to get access

Abstract

The ETV6/RUNX1 fusion gene is a valuable prognostic marker that is frequently observed in B-cell precursor acute lymphoblastic leukemia (B-cell ALL). However, the clinical significance of copy number aberrations in these genes remains unclear. In this study, the effects of various aberrations inETV6 and RUNX1 gene copy number on disease prognosis were evaluated in 21 pediatric patients diagnosed with B-cell ALL with/without t(12;21). The prognostic significance of changes in gene copy number of ETV6 or RUNX1 in the presence or absence of hyperdiploidy, trisomy 21, and t(12;21) translocation were also evaluated. RUNX1 gene copy number amplifications were detected in 83 % of the patients who lacked t(12;21) and in all of the patients with hyperdiploidy. Trisomy 21 was detected in 78 % of the patients with hyperdiploidy. Changes in ETV6 gene copy number were detected in patients who lacked both the t(12;21) translocation and RUNX1 gene copy number amplifications. However, RUNX1 gene copy number amplification and ETV6 deletion were observed in all of the patients with t(12;21). RUNX1 gene copy number amplification was associated with hyperdiploidy, but not with t(12;21). Thus, the evaluation of distinct FISH and cytogenetic patterns in patients with B-cell ALL may strengthen the prognostic significance of changes in gene copy number.
Literature
1.
De Braekeleera E, Douet-Guilberta N, Morela F, Le Bris MJ, Basinkoa A, Braekeleera M. ETV6 fusion genes in hematological malignancies: a review. Leuk Res. 2012;36(8):945–61.CrossRef
2.
Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2(7):502–13.CrossRefPubMed
3.
4.
De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Férec C, De Braekeleer M. RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncol. 2011; 7(1):77–91.
5.
Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23(24):4284–96.CrossRefPubMed
6.
Harada H, Harada Y. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome. Crit Rev Eukaryot Gene Expr. 2005;15(3):183–96.CrossRefPubMed
7.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–506.CrossRefPubMedPubMedCentral
8.
Wood LD, Irvin BJ, Nucifora G, Luce KS, Hiebert SW. Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proc Natl Acad Sci USA. 2003;100(6):3257–62.CrossRefPubMedPubMedCentral
9.
Al-Shehhi H, Konn ZJ, Schwab CJ, Erhorn A, Barber KE, Wright SL, et al. Abnormalities of the der(12)t(12;21) in ETV6-RUNX1 acute lymphoblastic leukemia. Genes Chromosom Cancer. 2013;52(2):202–13.CrossRefPubMed
10.
Barbany G, Andersen MK, Autio K, Borgström G, Franco LC, Golovleva I, et al. Additional aberrations of the ETV6 and RUNX1 genes have no prognostic impact in 229 t(12;21)(p13;q22)-positive B-cell precursor acute lymphoblastic leukaemias treated according to the NOPHO-ALL-2000 protocol. Leuk Res. 2012;36(7):936–8.CrossRefPubMed
11.
Ko DH, Jeon Y, Kang HJ, Park KD, Shin HY, Kim HK, et al. Native ETV6 deletions accompanied by ETV6-RUNX1 rearrangements are associated with a favourable prognosis in childhood acute lymphoblastic leukaemia: a candidate for prognostic marker. Br J Haematol. 2011;155(4):530–3.CrossRefPubMed
12.
Hutspardol S, Pakakasama S, Kanta K, Nuntakarn L, Anurathapan U, Sırachaınan N, et al. Interphase-FISH screening for eight common rearrangements in pediatric B-cell precursor acute lymphoblastic leukemia. Int J Lab Hematol. 2013;35(4):406–15.CrossRefPubMed
13.
Bokemeyer A, Eckert C, Meyr F, Koerner G, von Stackelberg A, Ullmann R, et al. Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia. Haematologica. 2014;99(4):706–14.CrossRefPubMedPubMedCentral
14.
Pombo-de-Oliveira MS, Emerenciano M, Winn AP, Costa I, Mansur MB, Ford AM. Concordant B-cell precursor acute lymphoblastic leukemia in non-twinned siblings. Blood Cells Mol Dis. 2015;54(1):110–5.CrossRefPubMed
15.
Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3(9):639–49.CrossRefPubMed
16.
Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. 2014;28(5):1015–21.CrossRefPubMed
17.
Garcia DR, Arancibia AM, Ribeiro RC, Land MG, Silva ML. Intrachromosomal amplification of chromosome 21 (iAMP21) detected by ETV6/RUNX1 FISH screening in childhood acute lymphoblastic leukemia. Rev Bras Hematol Hemoter. 2013; 35(5):369–71.
18.
Heerema NA, Carroll AJ, Devidas M, Loh ML, Borowitz MJ, Gastier-Foster JM, et al. Intrachromosomal amplification of chromosome 21 ıs associated with ınferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group. J Clin Oncol. 2013;31(27):3397–402.CrossRefPubMedPubMedCentral
19.
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18–24.PubMed
20.
Czepulkowski B. Basic techniques for the preparation and analysis of chromosomes from bone marrow and leukemic blood. In: Rooney DE, editor. Human cytogenetics malignancy and acquired abnormalities, 3rd edn. Oxford University Press, Oxford; 2001. pp. 1–26
21.
22.
Katsibardi K, Braoudaki M, Karamolegou K, Tzortzatou-Stathopoulou F. Clinical outcome of the coexistence of ETV6/RUNX1 and high hyperdiploidy in pediatric acute lymphoblastic leukemia. Leuk Lymphoma. 2014;55(8):1946–8.CrossRefPubMed
23.
Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell CD, et al. Risk-directed treatment ıntensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and ıntrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol. 2013;31(27):3389–96.CrossRefPubMed
24.
Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2011;117(25):6848–55.CrossRefPubMed
25.
Moosavi SA, Sanchez J, Adeyinka A. Marker chromosomes are a significant mechanism of high-level RUNX1 gene amplification in hematologic malignancies. Cancer Genet Cytogenet. 2009;189(1):24–8.CrossRefPubMed
26.
Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. 2013;27(2):295–304.CrossRefPubMed
27.
Krstic AD, Impera L, Guc-Scekic M, Lakic N, Djokic D, Slavkovic B, et al. A complex rearrangement involving cryptic deletion of ETV6 and CDKN1B genes in a case of childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2009;195(2):125–31.CrossRefPubMed
28.
Chae H, Kim M, Lim J, Kim Y, Han K, Lee S. B lymphoblastic leukemia with ETV6 amplification. Cancer Genet Cytogenet. 2010;203(2):284–7.CrossRefPubMed
29.
Mauvieux L, Helias C, Perrusson N, Lioure B, Sorel N, Brizard F, et al. ETV6 (TEL) gene amplification in a myelodysplastic syndrome with excess of blasts. Leukemia. 2004;18(8):1436–8.CrossRefPubMed
Metadata
Title
Prognostic impact of RUNX1 and ETV6 gene copy number on pediatric B-cell precursor acute lymphoblastic leukemia with or without hyperdiploidy
Authors
Nuket Yurur Kutlay
Esra Pekpak
Sule Altıner
Talia Ileri
Arzu Nedime Vicdan
Handan Dinçaslan
Elif Unal Ince
Fatma Ajlan Tukun
Publication date
01-09-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2034-y

Other articles of this Issue 3/2016

International Journal of Hematology 3/2016 Go to the issue

Case Report

Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma

Rapid Communication

Transition of adult T-cell leukemia/lymphoma clones during clinical progression

Review Article

Regulation of hematopoietic development by ZBTB transcription factors

Case Report

Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide

Original Article

The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy

Original Article

Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits